Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: Study based on an enzyme-linked assay and immunohistochemical staining

被引:21
|
作者
Endo T. [1 ]
Nakabayashi K. [1 ]
Sekiuchi M. [1 ]
Kuroda T. [1 ]
Soejima A. [1 ]
Yamada A. [1 ]
机构
[1] First Department of Internal Medicine, Kyorin University, School of Medicine, Mitaka, Tokyo 181-8611
关键词
Glomerulonephritis; Metalloproteinase; Tissue inhibitor of metalloproteinase;
D O I
10.1007/s10157-006-0438-3
中图分类号
学科分类号
摘要
Background. Various glomerular diseases progress to end-stage renal failure due to an accumulation of the mesangial matrix (MM) and a thickening of the glomerular basement membrane (GBM). Both the MM and GBM are consistently metabolized through the synthesis and destruction of the matrix. Such synthesis is influenced by transforming growth factor-β (TGF-β) and other factors, whereas the destruction is presumed to be mediated by both matrix metalloproteinases (MMPs) and inhibitors of matrix metalloproteinases (TIMPs). Based on such evidence, we tried to detect MMP-2, MMP-9, and TIMP-1 in the peripheral blood of patients with various glomerular diseases. Methods. Serum was used to detect MMP-2 and TIMP-1, while plasma was used to detect MMP-9. These enzymes were detected using an enzyme-linked assay. Results. The findings showed an increased level of MMP-2 in patients with a alteration of GBM, typically membranous nephropathy (MN), regardless of the differences in their etiological processes. In contrast, MMP-9 did not show a strong association with any specific glomerular abnormalities. However, it mainly tended to increase in patients with MM accumulation. In addition, the localization of MMP-2, MMP-9, and TGF-β1 was studied using immunohistochemical staining. MMP-2 was demonstrated to exist in the glomerular capillary loop (GCL) as well as in the mesangial cells and the mesangial matrix. MMP-9 was found to exist in mesangial cells and the matrix, GCL, infiltrated neutrophils, and some tubular epithelial cells. Positive staining for TGF-β1 in GCL was found to be associated with an increased level of MMP-2 in patients with MN, whereas in MM such positive staining was not necessarily associated with an increased level of MMP-9. Conclusions. These results therefore suggest that MMP-2 plays an important role in the degradation of GBM, while MMP-9 only moderately affects the degradation of MM. © 2006 Japanese Society of Nephrology.
引用
收藏
页码:253 / 261
页数:8
相关论文
共 50 条
  • [21] Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in healthy and type 2 diabetic subjects
    Derosa, Giuseppe
    D'Angelo, Angela
    Tinelli, Carmine
    Salvadeo, Sibillaa. T.
    Ciccarelli, Leonardina
    Piccinni, Mario N.
    Pricolo, Fabio
    Montagna, Lorenza
    Ghelfi, Morena
    Ferrari, Ilaria
    Gravina, Alessia
    Cicero, Arrigo F. G.
    DIABETES, 2006, 55 : A154 - A154
  • [22] Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells
    Constantinescu, CS
    Grygar, C
    Kappos, L
    Leppert, D
    CYTOKINE, 2001, 13 (04) : 244 - 247
  • [23] Immunohistochemical expression of matrix metalloproteinase-1, matrix metalloproteinase-2 and matrix metalloproteinase-9, myofibroblasts and Ki-67 in actinic cheilitis and lip squamous cell carcinoma
    Bianco, Bianca C.
    Scotti, Fernanda M.
    Vieira, Daniella S. C.
    Biz, Michelle T.
    Castro, Renata G.
    Modolo, Filipe
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2015, 96 (05) : 311 - 318
  • [24] Serum matrix metalloproteinase-9/tissue inhibitor of matrix metalloproteinase-1 and heart remodeling in patients with aortic stenosis after operation
    Goncharova, N.
    Moiseeva, O.
    Aleshina, G.
    Shlyakhto, E.
    JOURNAL OF HYPERTENSION, 2007, 25 : S45 - S45
  • [25] Genetic polymorphisms of matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1 and development of postoperative atrial fibrillation in elderly patients
    Rubanenko, O.
    Shchukin, Y.
    Rubanenko, A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 284 - 284
  • [26] Time course of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients presenting with acute coronary syndrome
    Bertsch, T
    Sueselbeck, T
    Wolpert, C
    Hoffmann, U
    Kaden, JJ
    Haase, KK
    Borggrefe, M
    Brueckmann, M
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2005, 43 (06) : 660 - 663
  • [27] Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in patients with tick-borne encephalitis
    Palus, Martin
    Zampachova, Eva
    Elsterova, Jana
    Ruzek, Daniel
    JOURNAL OF INFECTION, 2014, 68 (02) : 165 - 169
  • [28] IVIg decreases matrix metalloproteinase-9 production, not tissue inhibitor of metalloproteinase-1, by PBMC of multiple sclerosis patients
    Okada, K.
    Tsuji, S.
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 209 - 210
  • [29] Matrix metalloproteinase-2 and-9 and tissue inhibitor of metalloproteinase-1 and-2 in sera and urine of patients with renal carcinoma
    Di Carlo, Angelina
    ONCOLOGY LETTERS, 2014, 7 (03) : 621 - 626
  • [30] Clinical Significance of the Measurements of Serum Matrix Metalloproteinase-9 and Its Inhibitor (Tissue Inhibitor of Metalloproteinase-1) in Patients With Pancreatic Cancer Metalloproteinase-9 as an Independent Prognostic Factor
    Mroczko, Barbara
    Lukaszewicz-Zajac, Marta
    Wereszczynska-Siemiatkowska, Urszula
    Groblewska, Magdalena
    Gryko, Mariusz
    Kedra, Boguslaw
    Jurkowska, Grazyna
    Szmitkowski, Maciej
    PANCREAS, 2009, 38 (06) : 613 - 618